Filing Details
- Accession Number:
- 0001213900-22-007592
- Form Type:
- 13G Filing
- Publication Date:
- 2022-02-13 19:00:00
- Filed By:
- Cantor Fitzgerald Securities
- Company:
- Cero Therapeutics Holdings Inc.
- Filing Date:
- 2022-02-14
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Cantor Fitzgerald Securities | 0 | 750,000 | 0 | 750,000 | 750,000 | 4.1% |
| Cantor Fitzgerald Co | 0 | 155,000 | 0 | 155,000 | 155,000 | 0.8% |
| Cantor Fitzgerald | 0 | 905,000 | 0 | 905,000 | 905,000 | 4.9% |
| CF Group Management, Inc | 0 | 905,000 | 0 | 905,000 | 905,000 | 4.9% |
| Howard W. Lutnick | 0 | 905,000 | 0 | 905,000 | 905,000 | 4.9% |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Amendment No. 1)*
Under the Securities Exchange Act of 1934
| Phoenix Biotech Acquisition Corp. |
| (Name of Issuer) |
| Class A Common Stock, par value $0.0001 per share |
| (Titles of Class of Securities) |
| 71902K204 |
| (CUSIP Number) |
| December 31, 2021 |
| (Date of Event Which Requires Filing of this Statement)
|
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ☐ | Rule 13d-1(b) |
| ☒ | Rule 13d-1(c) |
| ☐ | Rule 13d-1(d) |
| * | The remainder of this cover page shall be filled out of a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 71902K204 | SCHEDULE 13G | Page 2 of 11 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Cantor Fitzgerald Securities | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☐ |
| 3 | SEC USE ONLY
| |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
New York |
| NUMBER OF BY EACH | 5 | SOLE VOTING POWER
0 |
| 6 | SHARED VOTING POWER
750,000* | |
| 7 | SOLE DISPOSITIVE POWER
0 | |
| 8 | SHARED DISPOSITIVE POWER
750,000* |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
750,000* | |
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
| ☐ |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.1% | |
| 12 | TYPE OF REPORTING PERSON
PN |
FOOTNOTE:
| * | Consists of 750,000 shares of common stock, currently held in units. |
| CUSIP No. 71902K204 | SCHEDULE 13G | Page 3 of 11 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Cantor Fitzgerald & Co. | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☐ |
| 3 | SEC USE ONLY
| |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
New York |
| NUMBER OF BY EACH | 5 | SOLE VOTING POWER
0 |
| 6 | SHARED VOTING POWER
155,000* | |
| 7 | SOLE DISPOSITIVE POWER
0 | |
| 8 | SHARED DISPOSITIVE POWER
155,000* |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
155,000* | |
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
| ☐ |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.8% | |
| 12 | TYPE OF REPORTING PERSON
BD |
FOOTNOTE:
| * | Consists of 155,000 shares of common stock, currently held in units. |
| CUSIP No. 71902K204 | SCHEDULE 13G | Page 4 of 11 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Cantor Fitzgerald, L.P. | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☐ |
| 3 | SEC USE ONLY
| |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
| NUMBER OF BY EACH | 5 | SOLE VOTING POWER
0 |
| 6 | SHARED VOTING POWER
905,000* | |
| 7 | SOLE DISPOSITIVE POWER
0 | |
| 8 | SHARED DISPOSITIVE POWER
905,000* |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
905,000* | |
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
| ☐ |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.9% | |
| 12 | TYPE OF REPORTING PERSON
PN |
FOOTNOTES:
| * | Consists of 905,000 shares of common stock, currently held in units. |
| CUSIP No. 71902K204 | SCHEDULE 13G | Page 5 of 11 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
CF Group Management, Inc. | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☐ |
| 3 | SEC USE ONLY
| |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
New York |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
0 |
| 6 | SHARED VOTING POWER
905,000* | |
| 7 | SOLE DISPOSITIVE POWER
0 | |
| 8 | SHARED DISPOSITIVE POWER
905,000* |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
905,000* | |
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
| ☐ |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.9% | |
| 12 | TYPE OF REPORTING PERSON
CO |
FOOTNOTES:
| * | Consists of 905,000 shares of common stock, currently held in
units. |
| CUSIP No. 71902K204 | SCHEDULE 13G | Page 6 of 11 |
| 1 | NAME OF REPORTING PERSON OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Howard W. Lutnick | |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☐ |
| 3 | SEC USE ONLY
| |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
United States |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
0 |
| 6 | SHARED VOTING POWER
905,000* | |
| 7 | SOLE DISPOSITIVE POWER
0 | |
| 8 | SHARED DISPOSITIVE POWER
905,000* |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
905,000* | |
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
| ☐ |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.9% | |
| 12 | TYPE OF REPORTING PERSON
IN |
FOOTNOTE:
| * | Consists of 905,000 shares of common stock, currently held in units. |
| CUSIP No. 71902K204 | SCHEDULE 13G | Page 7 of 11 |
| Item 1(a). | Name of Issuer: |
| Phoenix Biotech Acquisition Corp. | |
| Item 1(b). | Address of Issuer’s Principal Executive Offices: |
| 2001 MARKET STREET SUITE 3400 PHILADELPHIA PA 19103 2157319450 | |
| Item 2(a). | Name of Person Filing: |
| Cantor Fitzgerald Securities, Cantor Fitzgerald & Co., Cantor Fitzgerald, L.P., CF Group Management, Inc. and Howard W. Lutnick (collectively, the “Reporting Persons”).
The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Class A Common Stock reported herein.
| |
| Item 2(b). | Address of Principal Business Office or, if none, Residence: |
| 110 East 59th Street New York, New York 10022
| |
| Item 2(c). | Citizenship: |
| Each of Cantor Fitzgerald Securities and Cantor Fitzgerald & Co. is a general partnership formed in New York. Cantor Fitzgerald, L.P. is a Delaware limited partnership, CF Group Management, Inc. is a New York corporation and Mr. Lutnick is a citizen of the United States of America. | |
| Item 2(d). | Titles of Classes of Securities: |
| Class A Common Stock, par value $0.0001 per share. | |
| Item 2(e). | CUSIP Number: |
| 71902K204 |
| Item 3. | If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a(n): |
| (a) | ☐ | Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78o). | |
| (b) | ☐ | Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c). | |
| (c) | ☐ | Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c). | |
| (d) | ☐ | Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). | |
| (e) | ☐ | Investment adviser in accordance with §240.13d-1(b)(1)(ii)(E). | |
| (f) | ☐ | Employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F). | |
| (g) | ☐ | Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G). | |
| (h) | ☐ | Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813). | |
| (i) | ☐ | Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3). | |
| (j) | ☐ | Non-U.S. institution, in accordance with § 240.13d-1(b)(1)(ii)(J). | |
| (k) | ☐ | Group in accordance with §240.13d-1(b)(1)(ii)(K). | |
| If filing as a non-U.S. institution in accordance with §240. 13d-1(b)(1)(ii)(J), please specify the type of institution: __________ | |||
| CUSIP No. 71902K204 | SCHEDULE 13G | Page 8 of 11 |
| Item 4. | Ownership |
|
The responses to Items 5-11 of the cover pages of this Schedule 13G are incorporated herein by reference.
As of December 31, 2021, the Reporting Persons may be deemed to beneficially own an aggregate of 905,000 shares of Class A Common Stock, par value $0.0001 per share (“Common Stock”) of Phoenix Biotech Acquisition Corp. (the “Issuer”), representing 4.9% of the Issuer’s outstanding Common Stock.
The percentage of the Common Stock held by the Reporting Persons is based on 18,385,000 shares of Class A Common Stock reported to be outstanding as of November 19, 2021, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 filed with the Securities and Exchange Commission on November 19, 2021, and assumes no exercise of all the warrants held by the Reporting Persons.
Cantor Fitzgerald Securities ("CFS") and Cantor Fitzgerald & Co. ("CF&CO") are each the record holder of certain of the securities reported herein. CFS owns 750,000 shares of Common Stock and CF&CO owns 155,000 shares of Common Stock of the Issuer.
CF Group Management, Inc. (“CFGM”) is the managing general partner of Cantor Fitzgerald, L.P. ("Cantor") and directly or indirectly controls the managing general partners of CFS and CF&CO. Mr. Lutnick is Chairman and Chief Executive of CFGM and trustee of CFGM's sole stockholder. Cantor, indirectly, holds a majority of the ownership interests of each of CFS and CF&CO. As such, each of Cantor, CFGM and Mr. Lutnick may be deemed to have beneficial ownership of the securities directly held by CFS and CF&CO. Each such entity or person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest they may have therein, directly or indirectly.
|
| CUSIP No. 71902K204 | SCHEDULE 13G | Page 9 of 11 |
| Item 5. | Ownership of Five Percent or Less of a Class. |
| If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒. | |
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person. |
| Not Applicable. | |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. |
| Not Applicable. | |
| Item 8. | Identification and Classification of Members of the Group. |
| Not Applicable. | |
| Item 9. | Notice of Dissolution of Group. |
| Not Applicable. | |
| Item 10. | Certification. |
By signing below the undersigned certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
| CUSIP No. 71902K204 | SCHEDULE 13G | Page 10 of 11 |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
Dated: February 14, 2022
| CANTOR FITRZGERALD SECURITIES | ||
| By: | /s/ Howard W. Lutnick | |
| Name: Howard W. Lutnick | ||
| Title: Chief Executive Officer | ||
CANTOR FITZGERALD & CO. | ||
| By: | /s/ Howard W. Lutnick | |
| Name: Howard W. Lutnick | ||
| Title: Chief Executive Officer | ||
CANTOR FITZGERALD, L.P. | ||
| By: | /s/ Howard W. Lutnick | |
| Name: Howard W. Lutnick | ||
| Title: Chief Executive Officer | ||
CF GROUP MANAGEMENT, INC. | ||
| By: | /s/ Howard W. Lutnick | |
| Name: Howard W. Lutnick | ||
| Title: Chief Executive Officer | ||
| By: | /s/ Howard W. Lutnick | |
| Howard W. Lutnick | ||
[Schedule 13G/A Amendment 1 – Phoenix Biotech Acquisition Corp. – February 2022]
| CUSIP No. 71902K204 | SCHEDULE 13G | Page 11 of 11 |
Exhibit Index
| Exhibit No. | Description | |
| 99.1 | Joint Filing Agreement, dated as of February 14, 2022, by and among the Reporting Persons |